One of the fundamental mechanisms whereby the innate immune system coordinates inflammatory signal transduction is through Toll-like receptors (TLRs), which function to protect and defend the host organism by initiating inflammatory signaling cascades in response to tissue damage or injury. TLRs are positioned at the neuroimmune interface, and accumulating evidence suggests that the inflammatory consequences of TLR activation on glia (including microglia and astrocytes), sensory neurons, and other cell types can influence nociceptive processing and lead to states of exaggerated and unresolved pain. In this review, we summarize our current understanding of how different TLRs and their accessory or adaptor molecules can contribute to the development and maintenance of persistent pain. The challenges and opportunities of targeting TLRs for new treatment strategies against chronic pain are discussed, including the therapeutic context of TLR-mediated signaling in opioid analgesia and chemotherapy-induced pain. Considering the prevalence of persistent pain and the insufficient efficacy and safety of current treatment options, a deeper understanding of Toll-like receptors holds the promise of novel therapies for managing pathological pain.
Introduction
Preclinical studies have identified innate immune signaling as a major mechanism responsible for persistent pain. Germline-encoded receptors and effectors that recognize a limited number of invariant molecular patterns are a key feature of the innate immune system, which produce immediate and stereotyped immune responses that are integral for mounting an appropriate defense against sterile and pathogenic injuries across phylogeny (Leulier & Lemaitre, 2008) . Recognition of conserved ligands by the innate immune system involves several classes of receptors collectively known as pattern recognition receptors (PRRs), which discriminate molecular sequences and can be categorized by the ligands they identify, their cellular localization, and the functional outcomes they support (Janeway & Medzhitov, 2002) .
The family of Toll-like receptors (TLRs) were the first PRRs to be identified and have since been widely characterized for their essential contributions to innate immune signaling (Kawai & Akira, 2011) .
The discovery of TLRs originated from the identification of the protein Toll, which plays an essential role in dictating dorsoventral polarity during larval embryogenesis for the fruit fly Drosophila melanogaster (Anderson, Bokla, & Nüsslein-Volhard, 1985; Anderson, Jürgens, & Nüsslein-Volhard, 1985) . Toll was further identified as a transmembrane interleukin-1 (IL-1) receptor (IL-1R) homolog (Gay & Keith, 1991; Hashimoto, Hudson, & Anderson, 1988 ) that initiates immune responses in cultured Drosophila hemocytes (Rosetto, Engstrom, Baldari, Telford, & Hultmark, 1995) . The role of Toll as a molecular substrate of host defense was confirmed following the observation of its antifungal signaling properties in adult flies https://doi.org/10.1016/j.pharmthera.2017.10.006 (Lemaitre, Nicolas, Michaut, Reichhart, & Hoffmann, 1996) . A human homolog of Drosophila Toll (hence the nomenclature Tolllike) was soon cloned and characterized as a transmembrane protein capable of inducing nuclear factor-κB (NF-κB)-mediated transcription of the pro-inflammatory cytokines IL-1, IL-6, and IL-8 in human monocytes (Medzhitov, Preston-Hurlburt, & Janeway, 1997) . The discovery of this receptor (later renamed TLR4) provided the initial evidence for TLRs as regulators of mammalian immunity (see O'Neill, Golenbock, & Bowie, 2013 , for a detailed history). A total of 13 TLRs have since been identified between humans and rodents (humans functionally express TLR1 to TLR10, while rodents express TLR1 to TLR9, and TLR11 to TLR13).
There has been extraordinary interest in elaborating the signaling principles of TLRs to uncover their functions for maintaining tissue homeostasis, and how their dysfunction leads to detrimental outcomes ranging from unresolved inflammation to diseases of autoimmunity. Beyond their role as innate immune receptors for pathogenic invaders, there is considerable evidence that they are critical sensors of sterile, cellular injury, and coordinate nociceptive processing via inflammatory signaling. Here, we summarize the preclinical evidence and propose a framework for the contribution of TLR signaling and neuroimmune crosstalk in mediating persistent pain. Understanding the unique and shared contributions of TLRs in the development and maintenance of persistent pain may reveal promising opportunities for improving pain management.
Overview of pain neurobiology
Acute pain is protective and adaptive, warning the organism to escape danger, and to protect the site of tissue injury during healing. Such painful stimuli (e.g. mechanical, thermal, and chemical) are initially transduced by a range of ion channels and G-protein-coupled receptors that are expressed at peripheral nociceptor terminals (Basbaum, Bautista, Scherrer, & Julius, 2009; Peirs & Seal, 2016) . The action potential is conducted along these first-order nociceptive neurons, and transmitted at central synapses via neurotransmitters and neuropeptides that have the potential to excite a complex network of secondorder nociceptive projection neurons in the spinal and medullary dorsal horns (Peirs & Seal, 2016) . Second-order nociceptive projection neurons project to supra-spinal sites, such as thalamic nuclei, which further project to cortical and subcortical regions via third-order neurons, enabling the encoding and perception of the multidimensional pain experience (Wiech, 2016) . These nociceptive signals may be suppressed in the spinal cord through activation of local inhibitory interneurons that produce γ-aminobutyric acid (GABA) or glycine, and via descending serotonergic and noradrenergic projections from brainstem sites to the spinal cord. Such modulatory pathways serve to influence the response to, and perception of, pain (Ossipov, Dussor, & Porreca, 2010; Peirs & Seal, 2016) .
However, pain can also persist well beyond the resolution of the initial injury, as a consequence of ongoing inflammation (e.g. rheumatoid arthritis), or after damage to the nervous system (neuropathic pain). Persistent pain can also develop where a precipitating noxious stimulus is not well characterized (dysfunctional pain) -such as fibromyalgia or irritable bowel syndrome -and is poorly understood. Neuropathic and dysfunctional pain are believed to be the consequence of amplified sensory signals in the peripheral and central nervous systems. The underlying mechanisms of such sensitization have been extensively studied (Costigan, Scholz, & Woolf, 2009; Gold & Gebhart, 2010; Kuner, 2010; Latremoliere & Woolf, 2009) , facilitated by a vast array of rodent pain models (see Mogil, 2009 ). These investigations have revealed that sensitization is not solely driven by direct neuronal communication, but rather by crosstalk between neurons and non-neuronal cells, such as glia, leukocytes, and keratinocytes.
Neuroimmune contribution to sensitization underlying persistent pain
In response to high-threshold activity or damage of first-order neurons, infiltrating immune cells and resident non-neuronal cells are activated at peripheral nociceptor terminals, at the dorsal root ganglia (DRG) containing sensory neuron cell bodies, and at the spinal cord dorsal horn (Grace, Hutchinson, Maier, & Watkins, 2014; Ji, Chamessian, & Zhang, 2016; Old, Clark, & Malcangio, 2015) . A consequence of non-neuronal cell activation is release of immune mediators that promote peripheral and central sensitization through neuromodulation and dysfunctional synaptic plasticity. For example, proinflammatory cytokines like tumor necrosis factor (TNF) and IL-1β, as well as nitroxidative species, enhance excitatory neurotransmission by mechanisms including neurotransmitter exocytosis and increased synaptic strength (Gwak, Hassler, & Hulsebosch, 2013; Kawasaki, Zhang, Cheng, & Ji, 2008; Kronschläger et al., 2016; Reeve, Patel, Fox, Walker, & Urban, 2000; Yan & Weng, 2013) . Glutamate homeostasis is also impaired by these mediators, which induce downregulation and posttranslational modifications of glutamate transporters and glutamine synthetase (Chen et al., 2010; Yan, Yadav, Gao, & Weng, 2014) . These immune-derived molecules, together with growth factors such as brainderived neurotrophic factor (BDNF), further promote neuroexcitability in pain pathways by disinhibiting GABAergic and glycinergic control (Coull et al., 2005; Kawasaki et al., 2008; Yowtak et al., 2011; Zhang, Nei, & Dougherty, 2010) . In addition to secreted factors, non-neuronal cells in the spinal cord, in particular microglia, can sculpt synaptic elements through phagocytosis of neuronal structures, which can further disrupt the balance of excitatory and inhibitory neurotransmission encoding nociception through excessive pruning of GABAergic terminals (Batti et al., 2016) .
Noxious insults induce release of a host of neuronally-derived mediators -like adenosine triphosphate (ATP), chemokine (C-C motif) ligand 2 (CCL2), CCL21, neuregulin-1, and colony stimulating factor 1 (CSF-1) -which can activate non-neuronal cells, such as glia, via their cognate receptors (Abbadie et al., 2003; Biber et al., 2011; Calvo et al., 2010; Guan et al., 2016; Tsuda et al., 2003) . Toll-like receptor signaling has also emerged as a major pathway that mediates the activation of both neuronal and non-neuronal cells after injury and infection/inflammation. Here, we discuss the receptor subtypes responsible, their endogenous ligands that are released after injury, and the cell signaling pathways responsible for the production of soluble factors that mediate persistent pain.
Toll-like receptors

Pattern recognition after tissue injury
Beyond pathogen recognition, TLRs function to recognize molecular patterns of ligands that are associated with cellular stress, tissue damage, or cell death. These noxious endogenous ligands are known as damage-associated molecular patterns (DAMPs; also known as alarmins) and they encompass a wide array of structurally diverse endogenous compounds (Table 1) . Many of the DAMPs identified as putative TLR ligands are molecules typically sequestered within intracellular compartments, but become liberated into the extracellular milieu during stress or tissue injury, including heat shock proteins (HSPs), high-mobility group box protein 1 (HMGB1), S100 proteins, nucleic acids, and histone proteins, among many others (Piccinini & Midwood, 2010; Trotta, Porro, Calvello, & Panaro, 2014) . In addition, breakdown of the extracellular matrix caused by the injury or from injury-related protease secretion produces several DAMPs that are recognized by TLRs, including hyaluronic acid, fibrinogen, tenascin-C, and biglycan (Didangelos et al., 2016; Piccinini & Midwood, 2010) . Furthermore, oxidation of lipids from cellular membranes can also function as DAMP signaling molecules (Miller et al., 2003) . Evidence continues to accumulate that DAMP-mediated mechanisms of TLR activation are involved in initiating sterile inflammatory responses to tissue injury, which can occur in the absence of pathogen infiltration (Chen & Nuñez, 2010; Matzinger, 1994) . Understanding TLR recognition of DAMPs is particularly relevant for many hypotheses regarding neuroimmune mechanisms of nociception, where some mechanical, chemical, or immunological insult that results in tissue injury almost always predates the onset of persistent pain.
Structure homology, localization, and cell signaling
TLRs are type I transmembrane receptors with an N-terminal ectodomain containing a leucine-rich repeat motif, which folds into a solenoid structure to accommodate ligand recognition and accessory molecule interactions (Bell et al., 2005; Choe, Kelker, & Wilson, 2005) . Truncation of this ectodomain results in constitutive signaling, suggesting the solenoid structure is under baseline autoinhibition that is relieved by ligand interactions (Panter & Jerala, 2011) . The transmembrane element extending from the ectodomain leads to a C-terminal cytosolic Toll/interleukin-1 receptor (TIR) domain, which initiates downstream signaling processes through interactions with different adaptor proteins (Botos, Segal, & Davies, 2011) . Beyond these shared structural elements, TLR signaling complexes can begin to be differentiated by their subcellular localization; one group (TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10) is expressed primarily on the cell surface, while the second group (TLR3, TLR7, TLR8, and TLR9) is normally expressed in intracellular compartments such as endosomes, endoplasmic reticulum, or lysosomes (Fig. 1 ). These differences in subcellular distribution can further dictate the types of molecular patterns encountered from exogenous sources or as a consequence of tissue damage. Under homeostatic conditions, the cell-surface TLRs are monomeric but rapidly form homodimers or heterodimers when exposed to their cognate ligands; in contrast, several of the intracellular TLRs (e.g. TLR7 to TLR9) are synthesized as receptor dimers. In both cases, ligand binding produces conformational changes at the receptor interface to bring the cytosolic TIR domains into functional proximity (Gay, Symmons, Gangloff, & Bryant, 2014; Tanji, Ohto, Shibata, Miyake, & Shimizu, 2013) . Differences in receptor dimerization and recruitment of unique adaptor proteins allow for further distinction between TLRs in tuning downstream signaling outcomes (Lee, Avalos, & Ploegh, 2012; O'Neill & Bowie, 2007) .
TLRs are expressed by a wide variety of cells in rodents and humans (see Kato, Agalave, & Svensson, 2016) . Within the tissues of the nervous system, TLR expression has been identified on microglia, astrocytes, (Kim et al., 2007 Shi et al., 2011; Stokes, Cheung, et al., 2013) 2 (Brunn et al., 2017) 3 1 (Stokes, Cheung, et al., 2013) 2 (Qian et al., 2011) 1 (Bettoni et al., 2008; Hutchinson et al., 2008; Stokes, Cheung, et al., 2013; Tanga et al., 2005; Wu et al., 2010) 2 (Christianson et al., 2011) 3 (Brunn et al., 2017) 4 (Lan et al., 2010) 5 (Li et al., 2014 (Li et al., , 2015 Park, Stokes, et al., 2014; Shen et al., 2017) 6 (Grace et al., 2016) 7 (Sorge et al., 2011; Woller et al., 2016) 1 (Stokes, Cheung, et al., 2013) 2 (Das et al., 2016) 1 (Park, Xu, et al., 2014) 2 (Ichihara et al., 2017) oligodendrocytes, Schwann cells, satellite glial cells, fibroblasts, endothelial cells, macrophages, and sensory neurons (Bsibsi, Ravid, Gveric, & van Noort, 2002; Goethals, Ydens, Timmerman, & Janssens, 2010; Jack et al., 2005; Kim, You, Lim, & Lee, 2011; Laflamme & Rivest, 2001; Nagyőszi et al., 2010; Xu et al., 2015; Yao et al., 2015) . It is important to note that the regulation of TLR expression is highly dynamic and can vary under basal vs. inflammatory (or activated) conditions. In addition, some of the experiments determining TLR cellular expression are based on ex vivo preparations that can differ dramatically from physiological conditions, which could alter TLR expression or induce its transcription in cell types not expressing detectable levels in vivo. With these considerations in mind, the available in vitro and in vivo evidence demonstrate extensive TLR expression across many cell types. Despite their widespread expression, divergent outcomes can be elicited from TLR activation depending on its cellular localization. For instance, TLR2 expressed on bone marrow-derived inflammatory monocytes (Ly6C hi
Ly6G
− cells) can produce type I interferons (IFNs) in response to vaccinia virus, while this response is absent in TLR2-expressing plasmacytoid dendritic cells (Barbalat, Lau, Locksley, & Barton, 2009 (Kawai & Akira, 2010) . While each TLR can recognize a range of molecular patterns from exogenous and endogenous ligands, there is nevertheless specificity in terms of which ligands a given TLR can recognize, which permits the generation of appropriate immune response to the corresponding pathogen or DAMP (Akira & Takeda, 2004) (Table 1) . However, in general, ligand recognition by TLRs results in receptor dimerization, recruitment of adaptor proteins, and the induction of immune mediators (including inflammatory cytokines, chemokines, or IFNs) through downstream transcriptional regulation of target genes (for example, NF-κB or mitogen-activated kinases (MAPK)) (Fig. 1) . The functional outcomes of PRR activation includes opsonization of pathogens, cytoskeletal reorganization leading to phagocytosis, secretion of immune mediators (e.g. pro-inflammatory cytokines), and activation of the adaptive immune system, leading to general tissue inflammation and subsequent tissue repair (Medzhitov & Janeway, 2000) .
TLR-mediated neuroinflammatory signaling has been implicated in a variety of central nervous system (CNS) pathologies, including ischemic stroke, traumatic brain injury, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, and Alzheimer's disease (Buchanan, Hutchinson, Watkins, & Yin, 2010; Hanamsagar, Hanke, & Kielian, 2012; Xiang, Chao, & Feng, 2015) , in addition to some neuropsychiatric diseases ranging from depression (García Bueno, Caso, Madrigal, & Leza, 2016) to drug addiction (Lacagnina, Rivera, & Bilbo, 2017) . Adding to this panoply of conditions, there is also substantial Fig. 1 . Toll-like receptor signaling mechanisms. Toll-like receptors (TLRs) are essential for orchestrating inflammatory responses to protect and defend the host organism from invading pathogens and tissue damage. TLR1, TLR2, TLR4, TLR5, and TLR6 are primarily expressed at the cell surface, while TLR3, TLR7, TLR8, and TLR9 are typically found on endosomal compartments. Upon detection of cognate ligands, such as damage-associated molecular patters (DAMPs), TLRs form homodimers or heterodimers and undergo conformational changes, bringing cytosolic TIR domains into proximity and recruiting adaptor proteins to initiate intracellular signaling. TLR signal transduction involves MyD88 and/or TRIF adaptor proteins, which culminates in nuclear translocation of activated transcription factors and the production of inflammatory cytokines, immune mediators, and/ or interferons. Accessory proteins (CD14, CD36, MD-2) and other adaptor proteins (TIRAP, TRAM) dynamically interact with some TLRs to produce further selectivity of innate immune responses. The consequence of TLR-mediated gene transcription is the release of soluble mediators that can act on glia, immune cells, and neurons to produce nociceptive hypersensitivity. Abbreviations: AP-1, activator protein-1; CD, cluster of differentiation; CREB, cyclic adenosine monophosphate (cAMP) response element binding protein; DAMP, damage-associated molecular pattern; ERK, extracellular signalregulated kinase; IκBα, inhibitor of NF-κBα; IFN, interferon; IKK, inhibitor of NF-κB kinase; IL, interleukin; iNOS, inducible nitric oxide synthase IRAK, IL-1 receptor-associated kinase; IRF, IFN regulator factor; JNK, c-Jun N-terminal kinase; MD-2, myeloid differentiation factor 2; MyD88, myeloid differentiation primary response gene 88; NF-κB, nuclear factor-κB; TAK1, transforming growth factor β-activated kinase 1; TIR, Toll/interleukin-1 receptor; TIRAP, TIR domain containing adaptor protein; TLR, Toll-like receptor; TNF, tumor necrosis factor; TRAF, TNF receptor associated factor; TRAM, TRIF-related adaptor molecule; TRIF, TIRdomain-containing adaptor inducing interferon-β.
evidence for the involvement of TLRs in the chronic CNS dysfunction of pathological pain. In the following sections, we will cover individual TLRs and highlight evidence associating their function with the development and maintenance of pain, and how disruption of their signaling may offer therapeutic potential for ameliorating persistent pain.
TLR4
TLR4 signaling
Toll-like receptor 4 (TLR4) is the most extensively characterized of the TLRs based on its fundamental role in bacterial sensing and orchestration of the resulting inflammatory response. The canonical ligand for TLR4 is lipopolysaccharide (LPS), a component of the outer membrane of Gram-negative bacteria with a lipid moiety -known as lipid A (Strain, Fesik, & Armitage, 1983 ) -that produces an incredibly robust inflammatory immune response that can lead to sepsis if the immune response is not properly regulated (Roger et al., 2009) . The in vitro and in vivo immune response to LPS is dependent upon TLR4, as either spontaneous mutations in the Tlr4 gene (i.e. the dominate negative missense mutation in C3H/HeJ mice and homozygous null mutation in C57BL/10ScCr mice) or genetic knockout of Tlr4 (Tlr4 −/− mice) renders mice nonresponsive to LPS (Hoshino et al., 1999; Poltorak et al., 1998; Qureshi et al., 1999) . Recognition of LPS by TLR4 is multifaceted, requiring the coordination of multiple accessory proteins and a co-receptor. Circulating LPS-binding protein (LBP) brings LPS to the cell-surface receptor cluster of differentiation 14 (CD14), a chaperone protein that delivers LPS to the TLR4 complex (Schumann et al., 1990; Wright, Ramos, Tobias, Ulevitch, & Mathison, 1990 ) and dictates TLR4 receptor endocytosis (Zanoni et al., 2011) . Recognition of LPS requires the co-receptor myeloid differentiation factor 2 (MD-2), which provides a hydrophobic core that can bind the lipid A hexaacylated chain from LPS (Shimazu et al., 1999) . MD-2 occupies a space within the solenoid structure of TLR4 and stabilizes the active LPSbound complex, resulting in dimerization of TLR4 monomers and bringing the cytosolic TIR domains into proximity (Park et al., 2009 ). Subsequent conformational changes allow for the recruitment of adaptor proteins for the initiation of intracellular signaling cascades, primarily MyD88 and TRIF. MyD88 (myeloid differentiation primary response gene 88) is utilized by TLR4 and all other TLRs (with the exception of TLR3); its recruitment can lead to activation of NF-κB, MAPKs, activator protein-1 (AP-1), IFN regulatory factor 5 (IRF5), and IRF7, culminating in the transcription of cytokines, chemokines, and other immune mediators (Arthur & Ley, 2013; Medzhitov et al., 1998; Takaoka et al., 2005) . These include the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF) and inducible nitric oxide synthase (iNOS), but also anti-inflammatory IL-1R antagonist and IL-10. An alternative pathway involves recruitment of TRIF (TIR-domaincontaining adaptor protein inducing interferon-β), resulting in transcription factor IRF3-dependent regulation of type I IFNs (Yamamoto et al., 2003) , the expression of which has been associated with antiviral immunity and inhibition of nociceptive transmission (Liu, Gao, et al., 2016) . However, like MyD88, TRIF can result in nuclear translocation of NF-κB and cytokine transcription. Among the TLRs, TLR4 is unique in its capacity to signal through both MyD88-dependent and TRIF-dependent pathways (Fig. 1) . The mechanisms dictating how these pathways are selectively recruited is a matter of considerable interest. Although it is generally assumed that alternative TLR4 ligands engage similar signaling principles to those revealed by LPS, differential chemical or structural interactions with the TLR4/MD-2 complex may bias the inflammatory signaling.
Within the tissues of the nervous system involved in nociception, mRNA and/or protein for TLR4 is widely expressed on microglia (Zhang et al., 2013) but has also been identified on astrocytes (Liu, Han, et al., 2016) and primary sensory neurons, in particular the capsaicin-sensitive nociceptive neurons of the trigeminal ganglia (Wadachi & Hargreaves, 2006) and the DRG that co-express transient receptor potential vanilloid 1 (TRPV1) and ATP-gated ionotropic purinergic receptor P2X3 (Helley, Abate, Jackson, Bennett, & Thompson, 2015) . LPS can sensitize the firing rate of TRPV1-expressing sensory neurons to subsequent stimulation, thereby directly influencing neuronal hypersensitivity through TLR4-mediated mechanisms (Diogenes, Ferraz, Akopian, Henry, & Hargreaves, 2011; Li et al., 2015) . For immunocompetent non-neuronal cells such as microglia and astrocytes, there is agreement that the neuroimmune consequences of TLR4 activation (including secretion of TNF or IL-1β) can indirectly influence neuronal function in the context of nociceptive signaling . Additionally, while the immune mediators released from TLR4-expressing cells following receptor activation can aid in host defense, many are neurotoxic and must be quickly inactivated upon pathogen/ damage clearance to prevent additional neuronal injury. Indeed, direct agonism of TLR4 can be potently neurotoxic. Treatment of cultured spinal cord cells from mouse or chicken with high-dose LPS leads to neuronal death and axonal loss, an effect that is mirrored when dorsal root ganglion cells are co-cultured with mixed glial cells (Lehnardt et al., 2003) . Removing microglia from cultures or deriving cells from the Tlr4-mutant C3H/HeJ mouse strain prevented the neurotoxic effects of in vitro LPS (Lehnardt et al., 2003) . Using improved methods to resolve the cell type-specific contribution, it was recently demonstrated that activation and proliferation of microglia in the spinal cord (rather than infiltrating monocytes) are largely associated with the emergence of pain hypersensitivity following peripheral nerve injury (Gu et al., 2016) . These data position glia as essential regulators of TLR4-mediated toxicity and more generally as participants in the inflammatory events that are associated with pathological pain (Milligan & Watkins, 2009 ).
TLR4 and persistent pain
There is accumulating evidence for TLR4 as a critical receptor facilitating inflammatory responses that are associated with the pathology of persistent pain (Buchanan et al., 2010; DeLeo, Tanga, & Tawfik, 2004; Guo & Schluesener, 2007; Heiman, Pallottie, Heary, & Elkabes, 2014; Nicotra, Loram, Watkins, & Hutchinson, 2012) . Early work in preclinical models first identified alterations in Tlr4 gene expression in the CNS as a consequence of spinal cord injury that produces chronic pain. PCR analysis of spinal tissue following spinal L5 nerve transection revealed increased gene expression of Tlr4 and the chaperone protein Cd14 (Raghavendra, Tanga, & DeLeo, 2003; . The authors found mRNA expression of Tlr4 and Cd14 was rapidly induced at 4 hours post-injury with concomitant upregulation of the microglial activation marker integrin alpha M (Itgam, also known MAC-1 or CR3/CD11b), while astrocytic glial fibrillary acidic protein (Gfap) showed a delayed time-course of upregulation . This spinal nerve injury-induced Tlr4 upregulation was blocked by pre-or post-injury systemic administration of the drug minocycline, a putative glial modulator with non-selective pharmacological properties (Raghavendra et al., 2003) . Similar to L5 transection, increases in Tlr4 and Cd14 gene expression and TLR4 immunoreactivity in the rat spinal cord were also seen following an intraplantar injection of complete Freund's adjuvant, a model of peripheral inflammatory pain Zhao, Zhang, & Li, 2015) . These correlative observations led to more definitive demonstrations of the involvement of TLR4 in a preclinical model of painful neuropathy. Mice harboring Tlr4 mutations (i.e. the C3H/HeJ and C57BL/10ScCr strains) have attenuated mechanical hypersensitivity up to two weeks following spinal nerve transection, while rats given intrathecal treatment with TLR4 antisense oligonucleotide similarly reduced the behavioral hypersensitivity to spinal injury (Tanga, Nutile-McMenemy, & DeLeo, 2005) . Markers of microglial activation and cytokine production were also suppressed by oligonucleotide antagonism of TLR4 (Tanga et al., 2005) , supporting a role for spinal microglia as contributing to TLR4-mediated neuropathic pain.
The generality of TLR4's involvement in neuropathic pain was confirmed with pharmacological interventions in an animal model of peripheral nerve injury, namely the chronic constriction injury (CCI) of the sciatic nerve. This partial nerve ligation produces robust mechanical allodynia in rats that is reversed when differing TLR4 antagonists are delivered intrathecally (Hutchinson et al., 2008) , ranging from LPS-RS (LPS from Rhodobacter sphaeroides with TLR4 antagonistic properties, although its mechanism of action may vary under different conditions (Döring et al., 2017) ) to the TLR4 antagonists (+)-naloxone and (+)-naltrexone (which do not bind the stereoselective opioid receptors (Wang, Zhang, et al., 2016) ). Likewise, CCI-induced mechanical allodynia and thermal hyperalgesia in mice was reduced by systemic delivery of the TLR4 antagonist FP-1 (Bettoni et al., 2008) . Subcutaneous delivery of (+)-naloxone is also sufficient to acutely reverse spinal nerve ligation-induced allodynia in rats even when delivered months following injury (Lewis et al., 2012) , supporting TLR4 in the maintenance of ongoing pain. In agreement with these findings, intrathecal injection of TLR4 antagonist LPS-RS abrogates mechanical hypersensitivity in a mouse model of arthritic pain (Christianson et al., 2011) . While antagonism of TLR4 may help prevent dysregulated pain, engagement of TLR4 may help orchestrate some aspects of tissue repair in the context of nerve injury (Boivin et al., 2007) . Indeed, intraspinal injection of the synthetic TLR4 agonist E6020 accelerates myelin debris clearance, Schwann cell infiltration, and remyelination in the rat spinal cord (Church, Milich, Lerch, Popovich, & McTigue, 2017) . E6020 has lower affinity for TLR4 compared to LPS and shows less cross-reactivity with other TLRs, suggesting that proper tuning of TLR4 activation may lead to improved outcomes for demyelinating conditions with associated pain, such as spinal cord injury or multiple sclerosis.
Genetic perturbation of TLR4 provides further evidence for its role in nociceptive processing (Stokes, Cheung, Eddinger, Corr, & Yaksh, 2013; . In wild-type mice that receive unilateral L5 nerve ligation, there is a rapid development of mechanical allodynia in the ipsilateral paw with minimal effects on contralateral paw withdrawal thresholds. In contrast, male mice lacking functional TLR4 (Tlr4 −/− ) demonstrated partially attenuated mechanical hypersensitivity at later time points, which argues for the role of TLR4 in the transition from acute to chronic pain (Stokes, Cheung, et al., 2013) . Similar results were obtained when employing the K/BxN serum transfer arthritis model of persistent pain; the mechanical sensitivity of Tlr4 −/− mice gradually returned to baseline over weeks, while allodynia was maintained in wild-type mice (Christianson et al., 2011) . Furthermore, the absence of TLR4 reduces the severity of pain in an animal model of autoimmune neuropathy (P0 106-125 -induced experimental autoimmune neuritis) (Brunn et al., 2017) . Rather than complete loss-of-function from gene knockout, short interfering RNA (siRNA) can be locally delivered to knockdown gene transcription. In this manner, intrathecal delivery of siRNA against TLR4 ameliorates CCI-induced neuropathic pain while suppressing IL-1β and TNF protein release in the spinal cord following CCI (Wu et al., 2010) . Using a similar approach, early treatment of intrathecal siRNA to downregulate TLR4 prevents the expression of mechanical allodynia and spontaneous pain resulting from a rodent model of bone cancer (Lan et al., 2010) . This method of treatment was less efficacious as the tumor burden increased, pointing to a role for spinal TLR4 in the induction rather than maintenance of bone cancer pain.
In reflection of the anti-allodynic effects of TLR4 antagonism, intrathecal injection of the TLR4 agonist LPS is pro-allodynic in male (but not female) mice (Sorge et al., 2011) . This outcome may be driven by sexually dimorphic engagement of immune cells in the spinal cord (Sorge et al., 2015) , although this finding is not without controversy Krukowski et al., 2016; Staniland et al., 2010) . Similarly, intrathecal LPS-evoked tactile allodynia in mice is reduced in males by co-administration of the small molecule TLR4 antagonist TAK-242 while having no effect on females (Woller et al., 2016) . This leads to the intriguing possibility of sex differences regarding the involvement of innate immune signaling in the development of neuropathic tactile hypersensitivity. Given the predominance of chronic pain conditions disproportionately afflicting women, it has been argued that interactions between endocrine and immune mechanisms may help explain some of the sex differences observed in the epidemiology of pain disorders (Nicotra et al., 2012; Rosen, Ham, & Mogil, 2017) . These experiments underscore the importance of including males and females in both preclinical and clinical studies, and limits the generality of a proposed mechanism for pain if sex differences have not been considered.
There is general agreement that endogenous DAMPs recognized by TLR4 (see Trotta et al., 2014) are a likely culprit for TLR4-mediated pain. However, it is unclear which DAMPs are essential in the process, as the nature of DAMP recognition depends upon tissue composition and could vary greatly depending on the nature of the pain-inducing injury. Endogenous compounds that act as TLR4 ligands most likely operate on various timescales, from those acutely released to changes in the extracellular matrix composition that occur during the protracted process of tissue repair or under conditions of chronic inflammation. However, several putative TLR4 ligands have been identified in the context of pain (Table 1) . HSP60 is a chaperone protein involved in mitochondrial protein folding, but under conditions of cellular stress or injury it can be released from cells (Ohashi, Burkart, Flohé, & Kolb, 2000) . In primary culture of murine CNS cells, necrotic cells release HSP60, which results in a cycle of cell death by signaling at microglial TLR4 (Lehnardt et al., 2008 ). An additional member of the heat shock protein family, HSP90, can potentiate TLR4 signaling and augments LPS-induced mechanical allodynia (Hutchinson et al., 2009 ). Extracellular HMGB1 in the spinal cord has also been characterized as contributing to the development and maintenance of inflammatory pain in experimental arthritis based on its signaling through TLR4. Genetic or pharmacologic disruption of TLR4 blocked the pro-nociceptive effect of intrathecal HMGB1, which coincided with reduced spinal mRNA for glial activation and pro-inflammatory cytokine production (Agalave et al., 2014) . Only the partially oxidized disulfide HMGB1 isoform resulted in mechanical hypersensitivity (Agalave et al., 2014) , confirming that post-translational modifications of the redox state of HMGB1 influences its affinity for TLR4 or other receptors (Yang, Antoine, Andersson, & Tracey, 2013) . Tenascin-C, an extracellular matrix glycoprotein, is lowly expressed at baseline but can be persistently upregulated during conditions of inflammation. In a model of arthritic joint disease known to induce pain, the fibrinogen-like globe domain of tenascin-C can stimulate the release of TNF in a manner that requires TLR4 but not CD14 or MD-2, implying the contribution of an alternative co-receptor (Midwood et al., 2009) . Another interesting candidate is galectin-3, which is expressed on microglia and released after CNS injury (Lalancette-Hébert et al., 2012; Yip et al., 2017) and LPS stimulation (Burguillos et al., 2015) . Galectin-3 is found in the DRG and dorsal horn of the spinal cord, and its inhibition is associated with decreased pro-inflammatory glial activation and concurrent pain attenuation in preclinical models of peripheral nerve injury and herpetic allodynia (Ma, Han, Wang, Ai, & Zheng, 2016; Takasaki et al., 2012) . This TLR4-dependent microglial release of galectin-3 can produce a self-renewing cycle of paracrine TLR4 action and galectin-3 release, which could partially explain the propagation of inflammatory loops even after the initial injury has been resolved (Burguillos et al., 2015) .
TLR2
TLR2 signaling
Toll-like receptor 2 (TLR2) resides at the cell surface is characterized by an exceptional diversity of exogenous and endogenous molecular patterns it recognizes, including a variety of lipid moieties (Aliprantis et al., 1999; Brightbill et al., 1999) . This is due partly to its capacity for dimerizing with either TLR1 or TLR6, which expands the complexity of ligand specificity. Structural interrogation has confirmed TLR2 can distinguish a variety of lipopeptides by forming TLR2-TLR1 and TLR2-TLR6 heterodimers (Jin et al., 2007; Kang et al., 2009 ). Ligand-induced heterodimerization of the extracellular domains brings the cytosolic C-terminal TIR domains into proximity, which is postulated to initiate intracellular signaling through the MyD88-dependent pathway. Further complexity for ligand discrimination is conferred through interactions with co-factors such as CD36 and CD14 (Lee et al., 2012) . Although the endogenous DAMPs for TLR2 have not been definitively captured at this level of resolution, there is circumstantial evidence that TLR2 can bind to HMGB1, HSP60, biglycan, hyaluronan, and many others (Jiang et al., 2005; Park et al., 2004; Schaefer et al., 2005; Vabulas et al., 2001) . It is important to consider that, for the above citations, these DAMPs were not exclusively recognized by TLR2, as there appears to be extensive overlap between these endogenous ligands and their effects on TLR2 and TLR4. The capacity for directly ascribing a functional consequence exclusively to TLR2 depends on the methodology employed, but also emphasizes the substantial redundancy and crosstalk between TLRs and their downstream targets.
The expression of TLR2 in the peripheral and central nervous systems is primarily on microglia and other macrophages, although some TLR2 has been detected at low levels in astrocytes, oligodendrocytes, Schwann cells, fibroblasts, and endothelial cells, and neurons (Bsibsi et al., 2002; Fan, Frey, & Malik, 2003; Olson & Miller, 2004; Tang et al., 2007) . In the brain, RNA sequencing of purified cell populations shows Tlr2 gene expression is highly enriched in microglia compared to other cell types in the cortex (Zhang et al., 2014) .
TLR2 and persistent pain
Several lines of preclinical evidence have converged in support of TLR2 as contributing to persistent pain through neuroinflammatory mechanisms at nociceptive signaling pathways. Acute intrathecal delivery of a TLR2 agonist (heat killed Listeria monocytogenes) induces lasting tactile allodynia, but this pain response was absent in mice lacking functional Tlr2 . In mixed spinal cord glial cell culture from wild type mice, incubation with the supernatant of damaged sensory neurons produces numerous pro-nociceptive inflammatory genes, such as TNF, IL-1β, IL-6, and iNOS (Kim et al., 2007) . In contrast, glia isolated from Tlr2 −/− mutants show no change in cytokine and iNOS gene expression in response to damaged sensory neurons (Kim et al., 2007) . The authors further demonstrated that Tlr2-deficient mice have attenuated nerve transection-induced mechanical allodynia and thermal hyperalgesia compared to normal mice, which is accompanied by reduced glial activation and inflammatory gene expression in the spinal cord (Kim et al., 2007) . Nerve transection injury itself leads to increased TLR2 immunoreactivity in the spinal cord accompanied by increased microglial NADPH oxidase, an enzyme that produces reactive oxygen species (Lim, Kim, & Lee, 2013) . Beyond the spinal cord, the absence of Tlr2 in mice, like Tlr4, reduces markers of inflammation at the sciatic nerve in experimental autoimmune neuritis (Brunn et al., 2017) . Other authors have similarly found Tlr2 knockout to partially attenuate mechanical allodynia and thermal hyperalgesia induced by nerve ligation, although markers of glial activity in the lumbar spinal cord were still elevated ipsilateral to the nerve injury, compared to the contralateral lumbar laminae (Shi, Zekki, & Zhang, 2011; Stokes, Cheung, et al., 2013) . Differences in the severity of the peripheral injury (transection vs. ligation) and differing time points of glial assessment post-injury may explain the discrepancy in microglial and astrocyte activation in Tlr2 knockouts, while other groups have reported a dissociation between nociceptive hypersensitivity and conventional markers of "glial activation" (Ulmann et al., 2008) . Alternatively, infiltrating macrophages at the site of the peripheral injury may also participate in the pro-nociceptive inflammatory response, as macrophages at the site of the sciatic nerve injury overexpress TLR2 and show evidence of NF-κB activation (Shi et al., 2011) . Likewise, peripheral nerve injury results in macrophage infiltration at mouse DRGs along with upregulation of monocyte chemoattractant protein-1 (MCP-1, also known as CCL2), but these inflammatory responses were abrogated in Tlr2-knockout mice . Further characterizing the contribution of peripheral immune cells in chronic pain is advantageous for identifying pain biomarkers, as these cells are more readily accessible compared to the CNS. This is supported by patient data, where peripheral blood mononuclear cells isolated from patients suffering from chronic pain produce an exaggerated IL-1β response to TLR2, TLR4, and TLR7 agonists compared to pain-free controls (Kwok, Hutchinson, Gentgall, & Rolan, 2012) . Taken together, these results suggest that TLR2 engagement following nerve injury promotes conditions of neuropathic pain, which is likely driven by the inflammatory consequences of its activation.
TLR5
TLR5 signaling
Toll-like receptor 5 (TLR5) as a mammalian PRR is known primarily for its recognition of bacterial flagellin, a structural protein of both Gram-negative and Gram-positive bacteria that forms the whip-like filament of flagellum used for bacterial motility. In this regard, TLR5 is one of the few TLRs where the primary pathogen-associated molecular pattern is a protein. The crystal structure of zebrafish TLR5 reveals the D1 domain of flagellin as the sequence contributing to binding and signaling at the TLR5 ectodomain (Yoon et al., 2012) . Receptor dimerization leads to signaling through the adaptor protein MyD88, which as described earlier results in activation of NF-κB and increased transcription of pro-inflammatory cytokines (Gewirtz, Navas, Lyons, Godowski, & Madara, 2001; Hayashi et al., 2001 ). While TLR5 expression has been reported for microglia and astrocytes, often from primary glial cultures (Bowman, Rasley, Tranguch, & Marriott, 2003; Olson & Miller, 2004) , it is less clear the expression profile for glia in and around the spinal cord in vivo. However, both microglia and astrocytes cultured from rat spinal cord produce a robust TNF response to flagellin, implying some functional TLR5 is present under these conditions . Likewise, TLR5 protein and mRNA expression is observed in mouse primary DRG sensory neuron cell cultures (Goethals et al., 2010) . Deeper characterization by in situ hybridization and immunohistochemistry has revealed the presence of TLR5-expressing medium-to-large diameter myelinated Aβ-fibers in mouse DRGs; these sensory neurons were confirmed to innervate the hindpaw glabrous skin and project to the deep laminae of the dorsal horn of the spinal cord, a pattern consistent for low-threshold Aβ-fibers whose transition to dysregulated firing following injury may underpin mechanical allodynia (Xu et al., 2015) .
TLR5 and persistent pain
In comparison to the other cell-surface TLRs, TLR5 has received relatively little attention regarding its possible involvement in pain. However, a few articles have offered circuit-level and molecular insight into its potential role in different models of neuropathic pain. Reminiscent of the results obtained from Tlr4 −/− mice, mechanical allodynia due to L5 nerve ligation was attenuated in Tlr5 −/− mice, suggesting that full genetic deletion of Tlr5 influences pain processing (Stokes, Cheung, et al., 2013) . Current evidence indicates that under basal conditions, sensory A-fibers exclusively express TLR5 in the neuraxis (Xu et al., 2015) . Although it is not entirely clear what endogenous ligand might interact with TLR5 under physiological conditions, HMGB1 has emerged as a candidate DAMP. Purified HMGB1 elicits TLR5-mediated signaling under a variety of in vitro conditions, including NF-κB-dependent transcription of inflammatory effectors such as TNF, IL-8, and iNOS through the MyD88 signaling cascade (Das et al., 2016) . Importantly, in vivo injection of flagellin or HMGB1 into the hindpaw of rats produces acute allodynia, the latter of which could be abrogated with co-administration of the TLR5 antagonist TH1020 (Das et al., 2016) . Taken together, these data support the hypothesis that pain amplification can occur through endogenous recognition of extracellular HMGB1 through TLR5. While these initial insights have been promising, future work is necessary to determine if TLR5-HMGB1 interactions are involved in a more general sense in sensory processing across alternative pain models, or if its function is more narrowly engaged for allodynia. Moreover, it is unclear if glial or neuroimmune signaling contribute in TLR5-mediated pain states, as they do for other TLRs, or if DRGs are the primary cellular participant.
TLR3, TLR7, TLR9: Emerging roles of endosomal TLRs and persistent pain
The contributions of the endosomal TLRs to innate immunity have been extensively explored concerning their nucleic acid sensing within the cytoplasmic compartment, but little is known regarding their involvement in pain perception. However, there is some initial evidence to suggest that these TLRs could modulate pain through both shared and distinct molecular mechanisms. This was indirectly supported by the observation that DRGs express TLR3, TLR7, and TLR9 in culture, and delivering specific agonists for TLR3 (poly I:C), TLR7 (gardiquimod), and TLR9 (CpG oligodeoxynucleotide (ODN) 1826) each increase TRPV1 expression and functional activity of these sensory neurons, with concomitant increases in the release of pro-nociceptive prostaglandin E 2 (Qi et al., 2011) . In addition to DRGs, these endosomal-residing TLRs are thought to be expressed in varying degrees on microglia, astrocytes, oligodendrocytes, Schwann cells, fibroblasts, endothelial cells (Bsibsi et al., 2002; Goethals et al., 2010; Jack et al., 2005; Lehmann et al., 2012; Olson & Miller, 2004) .
TLR3
TLR3 recognizes double-stranded RNA (Alexopoulou, Holt, Medzhitov, & Flavell, 2001 ) and is unique among TLRs in that its activity is MyD88-independent; that is, it signals through the TRIF pathway, resulting in the release of type I interferons via IRF3 and/or inflammatory cytokines via NF-κB (Kawai & Akira, 2010) . Beyond the previous observations in cultured DRGs, there are few investigations into the relationship between TLR3 and pain. A recent investigation identified elevated TLR3 mRNA and protein in the rat spinal cord following nerve injury, along with increased activation of microglial autophagy in response to nerve injury or application of TLR3 agonists (Chen & Lu, 2017) . In a separate model of chronic pancreatitis, intrathecal infusion of TLR3 antisense oligodeoxynucleotide to knockdown TLR3 expression resulted in modest relief from mechanical allodynia (Qian et al., 2011) , suggesting TLR3 mechanisms participate under certain conditions of inflammatory pain. Activation of TLR3 may also serve to modulate neuropathic pain, as Tlr3-deficient mice show modest reductions in nerve injury-induced allodynia (Stokes, Cheung, et al., 2013) . What endogenous ligand would interact with TLR3 in the context of ongoing pain remains unclear, but host mRNA can act as a TLR3 ligand (Karikó, Ni, Capodici, Lamphier, & Weissman, 2004) .
TLR7
TLR7 recognizes single-stranded RNA as its primary ligand (Diebold, Kaisho, Hemmi, Akira, & Reis e Sousa, 2004) and within acidified endosomes signals through the MyD88-dependent pathway to release NF-κB-mediated inflammatory cytokines or IRF7-mediated transcription of type I IFNs. As with other TLRs, TLR7 expression has been noted in microglia and astrocytes but is also localized to primary sensory neurons, in particular TRPV1-expressing C-fiber DRGs (Liu, Xu, Park, Berta, & Ji, 2010). The cellular and molecular basis of TLR7 and its role in pain was identified through functional interaction between microRNAs (miRNA) and transient receptor potential ankyrin 1 (TRPA1) receptors on DRG neurons. As a single-stranded RNA, the endogenous miRNA lethal-7 (let-7) can function as a ligand for TLR7. When applied to DRGs, let-7b binds TLR7 and produces coupling to TRPA1 channels, resulting in a reliable increase of inward current that was abolished if the cells were deficient in Tlr7 or Trpa1 (Park, Xu, et al., 2014) . This mechanism of miRNA-induced hyperexcitability of nociceptors was supported behaviorally, as intraplantar injection of let7b produced nocifensive pain and allodynia that was dependent on Tlr7, Trpa1, and Myd88 but not Trpv1 (Park, Xu, et al., 2014) . The functional consequence of TLR7 activation by the agonist loxoribine has been further associated with increased bladder pain in female mice (Ichihara et al., 2017) . Thus, in a similar manner to TLR5, there is accumulating evidence that TLR-mediated signaling on neurons is functionally relevant for encoding sensory modalities such as pain.
TLR9
TLR9 is localized to the luminal surface of lysosomes and is activated by DNA with unmethylated CpG dinucleotides (Ahmad-Nejad et al., 2002; Hemmi et al., 2000) . Similar to TLR7, TLR9 signals through MyD88 to activate the transcription factor NF-κB for the production of pro-inflammatory cytokines TNF and IL-1β, or IRF7 for the production of IFNs. While TLR9 has been strongly implicated in autoimmune diseases (Marshak-Rothstein, 2006), its role in pain has been mostly unexplored. As with TLR4, direct stimulation of TLR9 appears to exacerbate neuronal injury through excessive glial release of TNF and nitric oxide (Iliev, Stringaris, Nau, & Neumann, 2004) . Blocking TLR9 activation with CpG ODN 2088 reduces inflammatory signaling and improves tumor-induced thermal hyperalgesia when delivered systemically (Qi et al., 2011) . Targeted inhibition of TLR9 by intrathecal delivery of the same compound reduces thermal sensitivity evoked by spinal cord injury, suggesting broader applicability across pain models (David et al., 2013) . While this anti-nociceptive behavioral effect was attributed to reduced inflammation, a subsequent mechanistic investigation determined that TLR9 antagonism with CpG ODN 2088 influences cultured spinal astrocytes and neurons uniquely, suppressing IL-6, CCL2, and CXCL1 cytokine and chemokine release from astrocytes while protecting neurons from kainic acid-induced excitotoxicity (Acioglu et al., 2016) . Evidence is lacking to identify what endogenous ligands may utilize this pathway after peripheral nerve injury. While these data implicate TLR9 in regulating thermal pain, its involvement in peripheral neuropathic pain has not been characterized.
TLR accessory and adaptor proteins
Much of the pleiotropic outcomes of TLR signaling are related to the diversity of co-factors involved in ligand discrimination and modification of downstream signaling. There is emerging evidence that these TLR accessory and adaptor proteins can contribute to enhanced nociceptive signaling, although it can be challenging to interpret which TLR or class of TLRs are directly implicated. For instance, the accessory protein CD14 significantly enhances TLR4 recognition of LPS and promotes immune responses for the TLR2-TLR6 heterodimer, but may also traffic ligands to endosomal TLR3, TLR7, and TLR9 (Lee et al., 2012) . CD14-mediated signaling may also contribute to neuropathic pain. In CD14-deficient mice (Cd14 -/-KO) that received L5 nerve transection, both mechanical allodynia and thermal hypersensitivity is reduced compared to wild-type injured mice (Cao, Tanga, & DeLeo, 2009) . Plasma fibronectin, a DAMP that parenchymal microglia are exposed to following vascular damage, induces a robust cytokine response (CCL2 and CXCL1) in mouse cells in a manner that requires CD14 (Janova et al., 2016) . Genetic deletion of Cd14 similarly attenuates microglial activation and monocyte recruitment after in vivo CNS injection of fibronectin or following CNS trauma and ischemic stroke (Janova et al., 2016) , all of which indicates CD14 may grant TLR4 (or other TLRs) some of its capacity for DAMP recognition and initiation of inflammatory events following certain injuries. The adaptor protein MyD88 is essential for nearly all TLR-mediated signaling. In nociceptive pathways (including DRG and spinal dorsal horn), CCI increases expression of MyD88 along with elevated levels of downstream phosphorylated NF-κB, phosphorylated extracellular signal-regulated kinase (ERK), and IL-1β (Liu et al., 2017) . Intrathecal delivery of MyD88 homodimerization inhibitory peptide is sufficient to attenuate both mechanical allodynia and thermal hyperalgesia (Liu et al., 2017) . Conditional deletion of Myd88 in Na v 1.8-expressing smallfiber sensory neurons alters neuropathic and inflammatory pain, although basal pain and acute inflammatory pain were unaffected . These data further substantiate a role for TLRs and their signaling partners in persistent pain, both in neuronal and nonneuronal cells.
Role of TLRs in opioid analgesia and chemotherapy-induced pain
The expanding notion of TLRs as sensors of damage or foreign compounds (i.e xenobiotics) has encouraged researchers to consider the extent that TLRs may accommodate xenobiotic-associated molecular patterns (XAMPs); that is, molecular motifs of non-pathogenic, non-self origin. Morphine, for instance, like other opioids, signal at receptors utilized by endogenous compounds (e.g. at μ opioid receptors), but the chemical structure and signaling kinetics of clinically-relevant opioid drugs differ from their endogenous opioid counterparts. Indeed, there is evidence that morphine and other opioids result in neuroinflammatory responses that are mediated in part through glial expression of TLR4 (Grace et al., 2016; Hutchinson et al., 2010) . Morphine binds to the hydrophobic core of MD-2 (similar to lipid A moiety from LPS) and induces TLR4 oligomerization, resulting in NF-κB-mediated release of IL-1β, TNF, and nitric oxide (Wang et al., 2012) . The implication of TLR engagement in response to opioids is paradoxical hyperalgesia -that is, increased sensitivity to pain following opioid exposure. The mechanisms dictating morphine-induced nociceptive sensitization were recently described and include TLR4 and its signaling through NLRP3 inflammasomes in microglia (Grace et al., 2016) . This is of particular clinical interest, given the widespread use of prescription opioids for acute and chronic pain management.
Chemotherapy-induced peripheral neuropathy (CIPN) is a serious adverse outcome related to the cytotoxic effects of chemotherapy agents and is characterized by a constellation of symptoms, most commonly paresthesia, dysesthesia, allodynia, or hyperalgesia in the hands and feet that can persist long after the discontinuation of treatment. The precise mechanisms leading to CIPN are still an area of active investigation, but there is now evidence from several sources that some classes of chemotherapeutics can directly interface with TLR complexes, which could contribute in part to the painful outcomes of CIPN. Paclitaxel is widely-used chemotherapeutic that exhibits anti-cancer properties by stabilizing cellular microtubules against disassembly, but repeated administration leads to painful peripheral neuropathy (Polomano, Mannes, Clark, & Bennett, 2001) . The observation that paclitaxel treatment resembles the pro-inflammatory response to LPS is supported by biochemical and structural evidence in murine and human cells that paclitaxel binds to MD2 and induces TLR4 oligomerization (Kawasaki et al., 2000; Wang et al., 2002; Zimmer, Liu, Clayton, Stephens, & Snyder, 2008) . The ability for structurally dissimilar molecules such as opioids or paclitaxel to bind MD-2 confirms the notion that no structural similarity to LPS is required to interact with TLR4/ MD-2 signaling complexes (Wang, Su, et al., 2016) . Functionally, TLR4 in the DRG contributes to paclitaxel-induced peripheral neuropathy by sensitizing TRPV1 + neurons (Li et al., 2014 (Li et al., , 2015 . Cisplatin, a platinum-based chemotherapy, is also clinically associated with CIPN, and the extent and duration of mechanical allodynia produced by cisplatin treatment was reduced in mice deficient in Tlr3, Tlr4, Myd88, and Trif, implying some partially overlapping yet indistinct inflammatory pathways contributing to allodynia (Park, Stokes, Corr, & Yaksh, 2014) .
These data implicate TLR complexes as potential therapeutic targets for CIPN, which could alleviate cancer morbidity and mortality that results from chemotherapy dose-reduction or discontinuation in the face of unresolved pain. It should be noted, however, that antagonism of TLR function during cancer treatment could negatively impact the prognosis of the patient. The contribution of TLRs in cancer is extraordinarily complex, and the outcomes of TLR-mediated inflammation and tissue repair have been associated with both inhibition and promotion of tumorigenesis (Rakoff-Nahoum & Medzhitov, 2009 ). The opposing roles of TLRs in cancer outcomes are exemplified in paclitaxel chemotherapy: while the drug can improve tumor clearance via TLR4-mediated antigen presentation and recruitment of adaptive cytotoxic T cells, its effect on systemic inflammation can recruit provascular progenitors to the tumor site and promote metastasis (Ran, 2015) . Notably, breast cancer cell growth is dichotomously controlled by TLR4 based on the mutation status of the tumor suppressor TP53, implying that TLR4 inhibition would suppress cancer growth in mutant tumors but promote cancer growth in wild-type tumors (Haricharan & Brown, 2015) . Thus, the future of pharmacologically targeting TLRs to prevent CIPN will require improved knowledge of which cancers may respond best to anti-TLR therapies.
Future directions and clinical implications
The prevalence of chronic pain is distressingly pervasive, with over 11% of adults in the United States reporting daily pain (Nahin, 2015) . Our inability to properly manage pain is thought to be a major contributing factor to the dramatic rise in overdose deaths from prescription opioid drugs, leading to over 33,000 deaths per year and an economic burden of an estimated $78 billion (Florence, Zhou, Luo, & Xu, 2016; Rudd, Seth, David, & Scholl, 2016) . These alarming statistics have led many to argue for increased research and investment in developing non-addictive analgesics (Grosser, Woolf, & FitzGerald, 2017) . To this end, the cumulative evidence reviewed here supports the intriguing concept that TLR-mediated signaling on glia and neurons can powerfully influence pain signaling and could represent a novel therapeutic target for managing pain. However, there are several outstanding questions that warrant consideration.
First, when interpreting the preclinical evidence reviewed here, there are experimental caveats worth considering. Animals with mutant or knockout alleles for TLRs are deficient across all cell types, which may have unrecognized consequences in biological systems not addressed by the investigators; that is, in these experiments it becomes difficult to attribute a genotype effect to resident or circulating immune cells, glia, neurons, alternative cells, or any combination therein. Moreover, not only have some TLR4 agonists been shown to signal around Tlr4 null mutations compared to Tlr4 knockouts (Goodridge et al., 2007) , but whole-body genetic deficiency in Tlr4 could result in compensatory or off-target confounding effects during development (Rossi et al., 2015) . Appropriate application of conditional and cell type-specific knockout animals can address some of these experimental concerns. Pharmacological agents aimed at manipulating receptor activity avoid developmental complications of the genetic models, but issues of bioavailablity and penetrance across the blood-brain barrier are limiting factors (García Bueno et al., 2016) ; moreover, questions of cell-type specificity usually cannot be addressed. Greater nuance is certainly needed for determining the cell type-specific localization and function of TLRs. Advanced cell sorting techniques have allowed immunologists to determine that the same TLR can have different signaling outcomes on different cells (Barbalat et al., 2009 ), but what this means in the context of pain is largely unknown.
There are additional concerns regarding the purported effects of some drugs, which may not function purely as TLR antagonists. As an example, Döring et al. (2017) recently discovered some agonistic effects of the presumptive antagonist LPS-RS when applied to murine microglia, both in culture and in vivo. This may call into question some of the data obtained that considered LPS-RS as a pure TLR4 receptor antagonist. While pharmacological and genetic techniques have still been extraordinarily informative, their limitations should still be considered when generating alternative explanations.
Second, despite excitement in the field regarding the contribution of TLRs to pain mechanisms, there are other PRRs not considered here that play essential roles in host immunity. There are several classes of PRRs that are localized in distinct cellular compartments, including those expressed at the plasma membrane (e.g. C-type lectin receptors (CLRs), dectins, and mannose receptors), those located at cytosolic membranes (e.g. nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) and retinoic acid-inducible gene 1 (RIG-I)-like receptors (RLRs)), or those that function as soluble factors (e.g. pentraxins, collectins, ficolins, and complement molecules), collectively representing both extracellular and intracellular signal detection (Medzhitov, 2009 ). Dynamic and flexible regulatory networks allow these innate immune factors to cross-modulate each other in additive or subtractive ways (Cao, 2016) . As an example, receptor for advanced glycation end-products (RAGE) is a PRR that shares overlapping features with many TLRs, such as its capacity for binding HMGB1, its signaling through p38 MAPK and c-Jun N-terminal kinase (JNK), and the resulting NF-κB-mediated transcription of pro-inflammatory immune molecules and oxidative species. Based on these similarities, others have implicated RAGE specifically, and PRRs more generally, as pathways for testing novel therapeutics against persistent pain (Allette et al., 2014; Kato et al., 2016) .
Third, additional research is needed to more definitively identify the endogenous ligands that are presumed to activate TLRs under conditions of painful injury. Because the crystal structures of TLR-DAMP complexes have not been reported, a significant question remaining is how individual DAMPs interact with TLR signaling complexes. Using TLR4 as an example, the reviewed DAMPs are assumed to activate TLR4/MD-2 in a manner reminiscent of LPS, although further structural data is needed to confirm this prediction. In addition, the degree to which TLRs may directly bind DAMPs, or whether TLR signaling is engaged through indirect facilitation of cellular damage is not entirely clear, as researchers are often limited in their ability to dissociate causative versus circumstantial evidence for the involvement of TLRs. Elucidation of endogenous ligand recognition could eventually lead to improved pharmacotherapies by allowing for rational drug design based on structural data, rather than basing TLR treatments based on interactions with pathogenic molecular patterns.
Finally, a major challenge arises when hypothesizing therapeutic agents: which TLR do you target? Do you target them all? Based on the largely preclinical work examined here, broadly blocking TLR receptor function is a potential treatment option. However, TLRs are so widely expressed, so varying in the neurophysiological outcomes they support, and so important for initiating innate immune responses, broad receptor antagonism could have unintended negative consequences. Pharmacotherapies designed at directly antagonizing TLRs will need to address the concerns of immunosuppression and whether these drugs can be given after the emergence of symptomatic pain. Identifying whether TLRs differentially contribute to some subsets of persistent pain may support selective targeting.
Further characterization of the DAMPs at the molecular, cellular, and systems level could lead to promising therapeutics targets that obviate the need for broad TLR antagonists. As an example, HMGB1 appears to be a shared ligand for the majority of TLRs covered here, and its extracellular release promotes hyperexcitability of peripheral sensory neurons leading to heightened states of pain (Feldman, Due, Ripsch, Khanna, & White, 2012) . The pro-nociceptive effect of spinal HMGB1 has been demonstrated in neuropathic and inflammatory pain conditions as well as bone cancer pain (Tong et al., 2010) , but additional evidence is needed to determine how specific TLRs contribute to this effect. Many of the pro-inflammatory cytokines or immune mediators that are transcribed as a consequence of TLR engagement can contribute to sensory neuron hyperexcitability as well, such as MCP-1/CCL2 (White et al., 2005) . CCL2 or other inflammatory products could be targeted for resolution, although a clinical trial to inhibit CCR2, the cognate receptor of CCL2, reported only trends in alleviating paroxysmal pain and paresthesia/dysesthesia (Källiomaki, et al., 2013) . While this methodology deserves further investigation, targeting individual immune mediators with small molecular inhibitors or neutralizing antibodies may be flawed, considering the list of molecules implicated in pain is vast and continues to grow. In this sense, developing methods for reducing transcription of the many pro-inflammatory mediators simultaneously could be a more effective approach. The positioning of MyD88 as a critical regulator for almost all TLR-mediated signaling makes it an attractive target for future investigation. Alternatively, utilizing anti-inflammatory cytokines as a means to resolve dysregulated inflammation during pain could also achieve this result. Such a treatment option has been tested in rodents, where gene therapy in the spinal cord to persistently upregulate expression of the anti-inflammatory cytokine IL-10 is successful at treating pain resulting from peripheral nerve injury, paclitaxel, and experimental autoimmune encephalomyelitis, a model of multiple sclerosis (Grace et al., 2017; Ledeboer et al., 2007; Milligan et al., 2006) . Similarly, a novel fusion protein of the anti-inflammatory cytokines IL-4 and IL-10 injected intrathecally reduces persistent inflammatory pain by inhibiting the activity of glial cells and their inflammatory products (Eijkelkamp et al., 2016) . This method is additionally advantageous by avoiding the application of plasmid or viral vectors.
An intriguing recent report provides convincing evidence that LPS from Gram-negative bacteria in the gut can act at TLR4 on endothelial cells in the brain and induce cerebral cavernous malformations (a major cause of hemorrhagic stroke and seizure), but these TLR-induced malformations could be prevented by influencing the microbiome (Tang et al., 2017) . This surprising link between the composition of the gut and a serious brain disorder has been echoed in the pain literature as well, where the typical mechanical hypersensitivity to inflammatory pain is reduced in germ-free mice lacking intestinal microbiota (Amaral et al., 2008) . Moreover, chemotherapy-induced mechanical hyperalgesia from oxaliplatin treatment is reduced follow eradication of the gut microbiota, and this effect depends, in part, on TLR4-expressing hematopoietic cells (Shen et al., 2017) . While speculative, manipulations to the composition of commensal microbiota could represent a strategy of influencing TLR function independent of typical pharmacological interventions.
Conclusion
Several decades of work have now clearly revealed that pain and inflammation are exquisitely entangled concepts. Here, we present evidence for Toll-like receptors as essential elements in the development and maintenance of persistent pain, although how each TLR contributes to pain does vary greatly based on its signaling properties and cellular location. To this end, future research should seek to further dissect how each TLR contributes to nociception, and how its expression on glial cells or neurons differentially influences its effects on pain processing. The rapid progress made in unraveling the signaling properties of TLRs in the context of pain transduction has been utterly remarkable, but the difficulty faced in translating the preclinical insights into effective therapies can be disheartening. Despite these challenges, fundamental insights into how TLRs and innate immune signaling contribute to the pathogenesis of persistent pain have offered hope for a new frontier in pain management, one that moves beyond simply altering neuronal firing and considers targeting the neuroinflammatory phenotypes that contribute to chronic pain (Ji, Xu, & Gao, 2014) . Continued elaboration of the role that each TLR plays in manifesting the pain experience is a promising opportunity for improving the treatment for the millions suffering each day in pain.
Conflict of interest statement
MJL and PMG declare there are no conflicts of interest. LRW is a cofounder of Xalud Therapeutics and a co-chair of the Xalud Therapeutics Scientific Advisory Committee.
